Related Experiment Video

Updated: Aug 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Lack of EGF receptor contributes to drug sensitivity of human germline cells

S-J Park1, S Armstrong, C-H Kim

  • 1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. slee@iupui.edu

British Journal of Cancer
|January 19, 2005
PubMed

Insights

Germline tumors show high sensitivity to DNA-damaging drugs due to low levels of epidermal growth factor receptor (EGFR). Restoring EGFR increases drug resistance in these cancer cells.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Pharmacology

Background:

  • Germline mutations are linked to various tumor types.
  • Understanding genetic alterations influencing drug sensitivity is crucial for cancer treatment.

Purpose of the Study:

  • To investigate genetic alterations in germline tumors affecting cellular drug sensitivity.
  • To explore the role of epidermal growth factor receptor (EGFR) in germline tumor drug response.

Main Methods:

  • Testing germline tumor cell hypersensitivity to DNA-damaging drugs.
  • Assessing DNA repair activity and protein expression.
  • Immunohistochemical analysis of EGFR expression in primary germline tumors.
  • Evaluating the effect of EGFR overexpression on drug resistance in germline tumor cells.

Main Results:

  • Germline tumor cells exhibited hypersensitivity to DNA-damaging drugs.
  • No significant alterations in DNA repair activity or protein expression were found.
  • Germline tumors showed significantly lower EGFR expression compared to drug-resistant ovarian cancer cells.
  • Overexpression of EGFR in germline tumor cells led to increased drug resistance.

Conclusions:

  • A lack of epidermal growth factor receptor (EGFR) contributes to the heightened drug sensitivity of germline tumors.
  • EGFR levels are a potential factor influencing therapeutic outcomes in germline cancers.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...